Health Care & Life Sciences » Biotechnology | Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
6,262.40
12,338.30
15,142.30
62,696.50
41,748.50
Total Accounts Receivable
-
-
1,330.40
-
-
Other Current Assets
270.60
376.50
930.30
2,808.20
2,491.80
Total Current Assets
6,533.00
12,714.80
17,402.90
65,504.70
44,240.30
Net Property, Plant & Equipment
54.00
124.10
435.30
1,432.70
2,705.20
Total Investments and Advances
13.70
36.40
50.00
-
-
Other Assets
-
-
-
40.80
43.80
Total Assets
6,600.80
12,875.30
17,888.20
66,978.20
46,989.30
ST Debt & Current Portion LT Debt
144.40
162.00
275.60
337.10
Accounts Payable
-
1,314.40
3,419.90
3,130.30
Other Current Liabilities
593.70
2,153.60
5,203.10
4,737.30
Total Current Liabilities
738.00
3,630.00
8,898.60
8,204.70
Long-Term Debt
-
-
4.60
0.40
Other Liabilities
-
260.30
65.70
989.60
Total Liabilities
738.00
3,890.30
8,968.90
9,194.60
Common Equity (Total)
5,862.70
8,985.00
8,919.20
57,783.60
Total Shareholders' Equity
5,862.70
8,985.00
8,919.20
57,783.60
Total Equity
5,862.70
8,985.00
8,919.20
57,783.60
Liabilities & Shareholders' Equity
6,600.80
12,875.30
17,888.20
66,978.20

About Corbus Pharmaceuticals Holdings

View Profile
Address
500 River Ridge Drive
Norwood Massachusetts 02062
United States
Employees -
Website http://www.corbuspharma.com
Updated 07/08/2019
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.